University of Florida Movement Disorders Center
Gainesville, Florida, 32611, United States
NCT Number: NCT01329198
The purpose of this trial is to determine whether a particular type of Deep Brain Stimulation (DBS), scheduled Deep Brain stimulation (SBS), is an effective and safe treatment for Tourettte syndrome (TS).
The trial will also examine the brain activity associated with TS and tics and explore the possibility of responsive brain stimulation (RBS).
Looking for future studies?
Notify Me25 year and older
All sexes
Interventional
Not applicable
Gainesville, Florida, 32611, United States
DBS is a surgical procedure that seeks to change the brain's electrical signalling by means of applied electrical current. To this end, a wire with tiny stimulating electrodes is implanted into one or both sides of the brain. An electrode is a small piece of metal used to take an electric current to or from a power source. These electrodes are connected under the skin on the scalp to a small electrical unit called an INS (implantable neurostimulator), which is similar to a heart pacemaker. The device sends out electrical impulses that appear to change the normal flow of electricity in the brain.
The wires which house the electrodes will be implanted on both sides of the brain oriented towards the centromedian thalamus-parafascicular complex. This region of the brain has to date the greats number of documented cases revealing significant improvements in motor tics.
This region of the brain will also provide a target where physiological changes related to motor tics are likely to be discovered.
The device we propose for this study has several features that make it more suitable for use in the TS population than other devices. It is self-contained in the skull and brain, and contains no tunneled neck connector wire and no chest pacemaker deice. This will help to lessen infection, and will assist in limiting device-related fractures due to tics involving neck region. Also, the system can record electro-encephalograph data from the area of the electrodes, which will assist us in gathering information about what specific physiological changes are correlated with tics.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Utilizes a signal that the device detects and will respond to with an electrical pre-defined pulse if the signal is encountered.
Other names: NeuroPace DBS (deep brain stimulation)
Time frame: Baseline to 6 Months
The Yale Global Tic Severity Scale (YGTSS) is a semistructured clinician-rated instrument that assesses the severity and frequency of motor and phonic tics over the previous week. Five index scores are obtained during the assessment, where higher scores indicate greater frequency or severity. These indices are:
The YGTSS Total Score is obtained by adding the Total Tic Score to the Overall Impairment Rating. The efficacy of the intervention will be assessed by comparing each subject's 6-month YGTSS Total Score to the pre-operative value for the same patient. Efficacy is considered 50% or greater reduction in this score.
Time frame: Baseline to 6 Months
Electrical recordings of electroencephalography activity were taken from each subject's implanted leads at each visit from baseline to 6 months. At baseline, the recordings were taken with the device in the off state (not stimulating), while at the 6 month visits the recordings were taken with the subject's device set to optimal parameters for tic control. Using Pearson's correlation coefficient, the variations in frequency and power which were observed were correlated with the Yale Global Tic Severity (YGTSS) scores obtained during primary outcome testing.
University of Florida
Other
Scheduled and Responsive Brain Stimulation for the Treatment of Tourette Syndrome
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05269953
Basal Ganglia Diseases, Brain Diseases
Nottingham, Nottinghamshire, United Kingdom
View Trial DetailsNCT03604510
Basal Ganglia Diseases, Brain Diseases
Bordeaux, France
View Trial DetailsNCT05628805
Basal Ganglia Diseases, Brain Diseases
Cincinnati, Ohio, United States
View Trial DetailsNCT04978428
Anxiety Disorders, Basal Ganglia Diseases
Chicago, Illinois, United States
View Trial Details